BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33803671)

  • 21. Application of next-generation sequencing in diffuse large B-cell lymphoma.
    Wang Y; Jia S; Cao X; Ge S; Yu K; Chen Y
    Pharmacogenomics; 2023 Jan; 24(1):59-68. PubMed ID: 36661028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP.
    Mondello P; Mian M
    Hematol Oncol; 2019 Oct; 37(4):333-344. PubMed ID: 30938848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy.
    Jardin F
    Discov Med; 2014; 18(97):51-65. PubMed ID: 25091488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
    He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
    J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma.
    Dybkaer K; Iqbal J; Zhou G; Chan WC
    Clin Lymphoma; 2004 Jun; 5(1):19-28. PubMed ID: 15245604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr Virus Infection of Cell Lines Derived from Diffuse Large B-Cell Lymphomas Alters MicroRNA Loading of the Ago2 Complex.
    Ayoubian H; Ludwig N; Fehlmann T; Menegatti J; Gröger L; Anastasiadou E; Trivedi P; Keller A; Meese E; Grässer FA
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances in the molecular diagnosis of diffuse large B-cell lymphoma.
    Fu K; Iqbal J; Chan WC
    Expert Rev Mol Diagn; 2005 May; 5(3):397-408. PubMed ID: 15934816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
    Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
    Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.
    Cao Y; Zhu T; Zhang P; Xiao M; Yi S; Yang Y; Li Q; Ling S; Wang Y; Gao L; Zhu L; Wang J; Wang N; Huang L; Zhang P; Zhai Q; Qiu L; Zhou J
    Oncotarget; 2016 Dec; 7(50):83294-83307. PubMed ID: 27825110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma.
    Harkins RA; Chang A; Patel SP; Lee MJ; Goldstein JS; Merdan S; Flowers CR; Koff JL
    Expert Rev Hematol; 2019 Nov; 12(11):959-973. PubMed ID: 31513757
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma.
    Puvvada S; Kendrick S; Rimsza L
    Cancer Genet; 2013; 206(7-8):257-65. PubMed ID: 24080457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
    Kwok M; Wu SP; Mo C; Summers T; Roschewski M
    Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular prognostic factors in diffuse large B-cell lymphoma.
    Morgensztern D; Lossos IS
    Curr Treat Options Oncol; 2005 Jul; 6(4):269-77. PubMed ID: 15967080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
    Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A B-cell-associated gene signature classification of diffuse large B-cell lymphoma by NanoString technology.
    Michaelsen TY; Richter J; Brøndum RF; Klapper W; Johnsen HE; Albertsen M; Dybkær K; Bøgsted M
    Blood Adv; 2018 Jul; 2(13):1542-1546. PubMed ID: 29967255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
    Dubois S; Viailly PJ; Mareschal S; Bohers E; Bertrand P; Ruminy P; Maingonnat C; Jais JP; Peyrouze P; Figeac M; Molina TJ; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Brière J; Petrella T; Canioni D; Fabiani B; Coiffier B; Delarue R; Peyrade F; Bosly A; André M; Ketterer N; Salles G; Tilly H; Leroy K; Jardin F
    Clin Cancer Res; 2016 Jun; 22(12):2919-28. PubMed ID: 26819451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
    Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
    J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.
    Croci GA; Au-Yeung RKH; Reinke S; Staiger AM; Koch K; Oschlies I; Richter J; Poeschel V; Held G; Loeffler M; Trümper L; Rosenwald A; Ott G; Spang R; Altmann B; Ziepert M; Klapper W
    Ann Oncol; 2021 Nov; 32(11):1400-1409. PubMed ID: 34438040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.